Synthesis and Bioactivity of Ancorinoside B, a Marine Diglycosyl Tetramic Acid.

The sponge metabolite ancorinoside B was prepared for the first time in 16 steps and 4% yield. It features a β-d-galactopyranosyl-(1→4)-β-d-glucuronic acid tethered to a d-aspartic acid-derived tetramic acid. Key steps were the synthesis of a fully protected d-lactose derived thioglycoside, its attachment to a C20-aldehyde spacer, functionalization of the latter with a terminal N-(β-ketoacyl)-d-aspartate, and a basic Dieckmann cyclization to close the pyrrolidin-2,4-dione ring with concomitant global deprotection. Ancorinoside B exhibited multiple biological effects of medicinal interest. It inhibited the secretion of the cancer metastasis-relevant matrix metalloproteinases MMP-2 and MMP-9, and also the growth of Staphylococcus aureus biofilms by ca 87% when applied at concentrations as low as 0.5 µg/mL. This concentration is far below its MIC of ca 67 µg/mL and thus unlikely to induce bacterial resistance. It also led to a 67% dispersion of preformed S. aureus biofilms when applied at a concentration of ca 2 µg/mL. Ancorinoside B might thus be an interesting candidate for the control of the general hospital, catheter, or joint protheses infections.

1. Introduction

Tetramic acids with glycosylated 3-acyl sidechains occur in nature as metabolites of bacteria, fungi/molds, and sponges. Their bioactivities span a broad spectrum, including antifungal, antibacterial, cytotoxic, and specific protein inhibitory effects [1,2,3,4]. They differ considerably in terms of structural complexity, culminating in compounds such as the aflastatins [5], which are fraught with functional groups and stereogenic centers. However, structural intricacy is not a prerequisite for biological activity. The ancorinosides A–D (1–4; Figure 1) were isolated from marine sponges Ancorina sp. and Penares sollasi by the groups of Ohta et al. [6] and Fusetani et al. [7]. They were found to inhibit membrane-type matrix metalloproteinases (MT1-MMPs) which are relevant for tumor growth and metastasis, and feature unadorned alkyl tethers and either a terminal β-d-glucopyranosyl-(1→4)-β-d-galacturonic acid (for 1 and 4) or a β-d-galactopyranosyl-(1→4)-β-d-glucuronic acid residue (for 2 and 3). Previously, we reported syntheses of ancorinosides A (1) [8] and D (4) [9], starting from d-glucose and d-galactose building blocks, and a d-aspartic acid ester. As this concept was not applicable to the disaccharide motif of ancorinosides B (2) and C (3), we now developed an alternative approach starting with inexpensive d-lactose.

Figure 1

Structures of ancorinosides A–D (1–4).

2. Results and Discussion

2.1. Synthesis of Ancorinoside B (2)

Our retrosynthetic approach is outlined in Scheme 1. The immediate precursor 5, a β-ketoamide bearing two carboxylic acids, was to undergo a base-induced Dieckmann cyclization to give the 2,4-pyrrolidinone, with concomitant cleavage of the methyl ester and benzoate protecting groups.

Scheme 1

Retrosynthesis of ancorinoside B (2).

Amide 5 should be prepared by an N-acylation [10] of N-methylated methyl d-aspartate 7 with unsaturated β-ketothioester 6, both having their carboxylic acids protected as benzyl esters, which were subsequently hydrogenated together with the alkene. Thioester 6 was thought accessible via Horner-Wadsworth-Emmons (HWE) olefination between an aldehyde 8 and readily available [10] phosphonate 9. While this sequence, so far, is reminiscent of the final steps of our route to ancorinoside A (1) [8], the synthesis of the required aldehyde 8, and its precursor disaccharides had to be planned distinctly different. Aldehyde 8 was to originate from β-selective glycosylation between a lactose-derived thioglycoside donor 10, fully benzoate protected except for the primary hydroxy group on the glucose moiety, and from a monoprotected 1,20-eicosanediol 11, followed by oxidation affording a uronic acid, its esterification, and eventually a deprotection and oxidation of the terminal hydroxy group.

The diglycoside donor 10 was prepared from commercially available, or readily synthesizable peracetylated d-lactose 12 in seven steps and 26% yield (Scheme 2). Compound 12 was substituted with 2-methyl-5-tert-butyl-thiophenol (MbpSH) at C-1 to leave thioglycoside 13 in 85% yield. Saponification of all acetates gave unprotected disaccharide 14 which was selectively protected in the galactose unit as a 4,6-benzylidene acetal 15 in 73% yield. Protection of the remaining primary alcohol as a tert-butyldiphenylsilyl (TBDPS) ether afforded compound 16. Removal of the 4,6-benzylidene acetal with ferric chloride furnished compound 17 which was per-benzoylated to give fully protected compound 18. Selective cleavage of the silyl ether eventually gave the desired diglycoside donor 10.

Scheme 2

Seven-step synthesis of diglycoside donor 10.

Donor 10 was then used to β-selectively glycosylate the monoprotected spacer diol 11 under standard conditions [11], affording tethered disaccharide 19 (Scheme 3). Alcohol 11 was prepared from eicosanedioic acid in two steps and 34% yield, analogously to the known TBS-protected congener [8]. Alcohol 19 was oxidized with bis(acetoxy)iodobenzene (BAIB)/TEMPO to uronic acid 20 in almost quantitative yield. Subsequent esterification gave benzyl ester 21 in 94% yield. Cleavage of the silyl ether with TBAF liberated 1-alkanol 22 which was oxidized to key aldehyde 8 with Dess-Martin periodinane (DMP).

Scheme 3

Synthesis of aldehyde 8.

Aldehyde 8 was chain-lengthened by a HWE olefination with Ley’s phosphonate 9 [ to give β-ketothioester 6 which was submitted to a silver-mediated coupling reaction with d-aspartate 7 furnishing β-ketoamide 23 (Scheme 4). The catalytic hydrogenation of both the alkene and the benzyl esters of the latter afforded compound 5, the immediate precursor to ancorinoside B (2). The latter was obtained upon a base-induced Dieckmann cyclization of the N-(β-ketoacyl) amino ester moiety of 5 with concomitant global deprotection of its diglycoside unit. The total yield over 16 steps was 4% (longest linear sequence). As Fusetani et al. [7] isolated and analyzed ancorinoside B as its tris(diethylammonium) salt, we also prepared this by treating target compound 2 with an excess of diethylamine in methanol. The 1H and 13C NMR data of our synthetic ammonium salt (NEt2H2)3[2–3H] are in good accordance with those published for the ammonium salt of the isolate (cf. Table S1 in the Supplementary Materials). While Fusetani et al. reported a specific optical rotation of [α]24D +1.5 (c 0.1, MeOH) for the ammonium salt, our synthetic products showed specific optical rotations of [α]24D +5.0 (c 0.1, MeOH) for the ammonium salt, and [α]24D +3.2 (c 0.1, MeOH) for the neutral ancorinoside B (2).

Scheme 4

Synthesis of ancorinoside B (2) and its tris(diethylammonium) salt.

2.2. Biological Activities of Ancorinoside B (2)

Synthetic ancorinoside B (2) was evaluated for antimicrobial (including antibiofilm) and cytotoxic activity against various bacteria, fungi, and cell lines. Its Minimum Inhibitory Concentration (MIC) values showed that it was only moderately to weakly active against four out of twelve species (Table 1). Against Bacillus subtilis with a MIC value of 16.6 μg/mL which is of the same order as the MIC = 4.2 µg/mL of oxytetracycline used as a positive control, against Staphylococcus aureus with MIC = 66.6 µg/mL (oxytetracycline: 0.4 µg/mL), against Mucor hiemalis with MIC = 66.6 μg/mL (positive control nystatin: 8.3 µg/mL), and against Rhodotorula glutinis with MIC = 66.6 µg/mL (nystatin: 2.1 µg/mL).

Table 1

Antimicrobial activity of synthetic ancorinoside B (2).

Tested Organisms	Strain No.	MIC [µg/mL]
		Ancorinoside B (2)	Reference 1
Bacteria
Bacillus subtilis	DSM 10	16.6	4.2 a
Staphylococcus aureus	DSM 346	66.6	0.4 a
Mycobacterium smegmatis	ATCC 700084	inactive	1.7 b
Acinetobacter baumannii	DSM 30008	inactive	0.5 c
Chromobacterium violaceum	DSM 30191	inactive	0.8 a
Escherichia coli	DSM 1116	inactive	3.3 a
Pseudomonas aeruginosa	PA 14	inactive	0.4 d
Fungi
Mucor hiemalis	DSM 2656	66.6	8.3 e
Pichia anomala	DSM 6766	inactive	8.3 e
Rhodotorula glutinis	DSM 10134	66.6	2.1 e
Candida albicans	DSM 1665	inactive	8.3 e
Schizosaccharomyces pombe	DSM 70572	inactive	4.2 e

1 References: a oxytetracycline, b kanamycin, c ciprobay, d gentamicin, e nystatin.

Ancorinoside B (2) also interfered with the formation and persistence of bacterial biofilms at concentrations far below its MIC and thus probably not inducing bacterial resistance via selection (Table 2). It inhibited the formation of biofilms of Staphylococcus aureus by 87% relative to untreated cultures at concentrations as low as 0.5 µg/mL, which is far superior to the known biofilm inhibitor microporenic acid A (MAA) [12], which led to a similar inhibition only at a high concentration of ca 31 µg/mL. Ancorinoside B (2) also led to the dispersion of preformed S. aureus biofilms to an extent of 67% when applied at a concentration of ca 2 µg/mL. In comparison, the positive control MAA, when applied at the maximum concentration of 250 µg/mL caused a dispersion of only ca 62%. Ancorinoside B (2) also dispersed 55% of preformed biofilms of Candida albicans, when applied at the highest concentration of 250 µg/mL. It is worthy of note that ancorinoside B (2) did not interfere in a similar manner with biofilms of Pseudomonas aeruginosa.

Table 2

Inhibition of biofilm formation of S. aureus and dispersion of preformed biofilms of S. aureus and C. albicans by ancorinoside B (2) at various concentrations.

Tested Organisms	Strain No.	Biofilm Inhibition[% ± SD]	Biofilm Dispersion[% ± SD]
		Ancorinoside B (2)
Staphylococcus aureus	DSM 1104	87 ± 3 (0.5 µg/mL) a	79 ± 4 (62.5 µg/mL) b67 ± 6 (2 µg/mL) b
		72 ± 4 (0.3 µg/mL) a
		22 ± 4 (0.13 µg/mL) a
Candida albicans	DSM 11225	–	55 ± 10 (250 µg/mL) c

References [%]: a microporenic acid A (MAA): 86 (31.3 µg/mL), 77 (7.8 µg/mL), 45 (3.9 µg/mL); b MAA: 62 (250 µg/mL), 40 (62.5 µg/mL), 48 (31.3 µg/mL); c farnesol: 81 (250 µg/mL), 70 (31.3 µg/mL), 38 (15.6 µg/mL); SD: standard deviation; –: not tested.

Synthetic ancorinoside B (2) was also tested for cytotoxicity against mouse fibroblast cells L929 and human endocervical adenocarcinoma KB3.1 cells, yet was found inactive. This bodes well for controllable toxicity in animals and humans.

Fusetani et al. [7] reported their isolated ancorinoside B (2) to inhibit the activity of purified membrane-type 1 matrix metalloproteinase and the downstream, tumor-relevant gelatinase A (MMP-2). We now examined whether synthetic ancorinoside B showed a similar effect on a cellular level by monitoring the expression and secretion of human cancer metastasis relevant MMP-2 and MMP-9 in treated 518A2 melanoma cells via gelatin zymography. In line with Fusetani et al. who reported an IC50 of 33 µg/mL (ca. 39 µM) for the inhibition of the activity of MMP-2 by their isolated ancorinoside B, we found that synthetic ancorinoside B reduced the secretion of human MMP-2 and MMP-9 by 518A2 melanoma cells in a concentration-dependent manner to ca 50% when applied at concentrations of 25–50 µM. It also reduced the expression of MMP-2 to ca 60% when applied at 50 µM (Figure 2 and Figure S1).

Figure 2

Effect of 500 nM to 50 µM of synthetic ancorinoside B (2; AncB) on the secretion of MMP-9 (A), the secretion of MMP-2 (B), and the expression of MMP-2 (C) in 518A2 melanoma cells; large error bars in C are due to blurry electrophoresis bands. DMSO (0 µM) served as a control.

3. Materials and Methods

3.1. General Information

Infrared spectra were recorded on a PerkinElmer Spectrum 100 FT-IR spectrophotometer(PerkinElmer, Rodgau, Germany) with an ATR sampling unit. Optical rotations were measured at 589 nm (Na-D line) on a PerkinElmer 241 polarimeter; [α]D values are quoted in 10−1 deg cm2 g−1. High-resolution mass spectra were recorded with a UPLC/Orbitrap MS system in ESI mode. NMR spectra were recorded with a Bruker Avance III HD 500 spectrometer (Bruker, Billerica, MA, USA; 1H NMR: 500 MHz and 13C NMR: 125 MHz). Chemical shifts are listed in parts per million relative to residual solvent peak as an internal standard, 7.26 ppm (proton) and 77.00 ppm (carbon) for CDCl3, 3.31 ppm (proton) and 49.15 ppm (carbon) for MeOD and 2.50 ppm (proton) and 39.51 ppm (carbon) for DMSO-d6. Coupling constants (J) are quoted in Hz. Multiplicities are quoted as: bs broad singlet, s singlet, d doublet, t triplet, q quartet, quin quintet, and m multiplet. Melting points were recorded on a Büchi Melting Point M-565 (Büchi Labortechnik, Flawil, Switzrland) and are uncorrected. All reagents were bought from Sigma-Aldrich (St. Louis, MO, USA) and TCI Chemicals (Zwijndrecht, Belgium) and were used without further purification. Anhydrous solvents were used as supplied, except THF and CH2Cl2 which were freshly distilled according to standard protocols. Reactions were routinely carried out under an argon atmosphere unless stated otherwise. All glassware was flame-dried prior to use. Analytical thin-layer chromatography (TLC) was carried out using Merck Kieselgel 60 F254 pre-coated aluminum-backed plates. Compounds were visualized with UV light (254 nm) and/or stained with ceric ammonium molybdate (CAM). Flash chromatography was performed at medium pressure using Macherey-Nagel (Macherey-Nagel, Düren, Germany) silica gel 60, pore size 40–63 μm with the eluent specified. Eicosan-1,20-diol, d-N-Me-Asp(OBn)-OMe (7) [8], S-tert-butyl 4-(diethoxyphosphono)-3-oxobutanethioate (9) [13] and β-d-lactose octaacetate (12) [14] were prepared according to literature procedures.

3.2. Compounds

(20-((tert-Butyldiphenylsilyl)oxy)eicosan-1-ol (11). A solution of eicosan-1,20-diol (12.2 g, 38.8 mmol) in pyridine (97 mL) was treated with TBDPSCl (1.10 mL, 42.7 mmol) and stirred for 24 h at 80 °C. H2O (150 mL) was added and the aqueous phase was extracted with CH2Cl2 (3 × 150 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in toluene (3 × 100 mL) and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 9:1) to give 11 (9.35 g, 16.9 mmol, 44%) as a colorless oil; R = 0.26 (n-hexane/EtOAc 9:1); 1H NMR (CDCl3, 500 MHz) δ 7.66–7.70 (m, 4H), 7.35–7.44 (m, 6H), 3.73–3.78 (m, 1H), 3.62–3.68 (m, 4H), 1.84–1.88 (m, 1H), 1.52–1.61 (m, 4H), 1.22–1.39 (m, 30H), 1.05 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 135.6, 134.2, 129.4, 127.5, 64.0, 63.1, 32.8, 32.6, 29.69, 29.67, 29.66, 29.61, 29.59, 29.43, 29.38, 26.9, 25.8, 25.7, 25.6, 19.2; IR νmax 3370, 2923, 2853, 1590, 1464, 1428, 1389, 1361, 1188, 1107, 1008, 938, 823, 738, 687, 700 cm–1; HRMS (ESI) m/z [M + H]+ calcd. for C36H61O2Si+, 553.44353; found 553.44366.

2′,3′,4′,6′-Tetra-O-acetyl-β-d-galactopyranosyl-(1→4)-(2,3,6-tri-O-acetyl-1-(tert-butyl-2-methylphenyl)thio-β-d-glucopyranoside (13). A solution of β-d-lactose octaacetate 12 (35.4 g, 52.1 mmol) in CH2Cl2 (130 mL) was treated with 5-tert-butyl-2-methylthiophenol (11.5 mL, 62.5 mmol) and BF3·Et2O (9.24 mL, 72.9 mmol), and stirred for 20 h at room temperature. 1M aqueous NaOH solution (200 mL) was added and stirring was continued for another 30 min. The aqueous phase was separated and extracted with CH2Cl2 (3 × 100 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 6:4) to give 13 (35.2 g, 44.1 mmol, 85%) as a colorless foam of mp 84–85 °C; R = 0.18 (n-hexane/EtOAc 7:3); [α]24D −5.3 (c 0.9, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.50 (d, J = 1.5, 1H), 7.24 (dd, J = 1.8, 7.9, 1H), 7.14 (d, J = 8.2, 1H), 5.34 (d, J = 2.4, 1H), 5.21 (t, J = 9.2, 1H), 5.09 (dd, J = 7.9, 10.3, 1H), 4.98 (t, J = 9.8, 1H), 4.94 (dd, J = 3.4, 10.4, 1H), 4.63 (d, J = 10.1, 1H), 4.47 (d, J = 7.9, 1H), 4.44 (d, J = 11.9, 1H), 4.03–4.16 (m, 3H), 3.86 (t, J = 6.6, 1H), 3.79 (t, J = 9.5, 1H), 3.56–3.64 (m, 1H), 2.35 (s, 3H), 2.14 (s, 3H), 2.09 (s, 3H), 2.09 (s, 3H), 2.04 (s, 6H), 2.02 (s, 3H), 1.95 (s, 3H), 1.31 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 170.3, 170.1, 170.0, 169.7, 169.6, 169.0, 149.7, 137.4, 131.4, 130.3, 130.0, 125.6, 101.1, 86.8, 76.5, 76.1, 73.9, 71.0, 70.7, 70.5, 69.0, 66.5, 62.4, 60.8, 34.4, 31.3, 20.85, 20.79, 20.77, 20.63, 20.60, 20.59, 20.5, 20.3; IR νmax 2964, 1745, 1432, 1367, 1213, 1171, 1137, 1042, 954, 901, 827, 721 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C37H50O17NaS+, 821.26609; found 821.26620.

β-d-Galactopyranosyl-(1→4)-1-(tert-butyl-2-methylphenyl)thio-β-d-glucopyranoside (14). A solution of 13 (22.4 g, 28.0 mmol) in MeOH (200 mL) was treated with NaOMe solution (3.83 mL, 25 wt% in MeOH) and stirred for 40 min at room temperature. The reaction mixture was acidified with DOWEX 50WX8-100® resin, filtered, and the filtrate was concentrated in vacuo to give 14 (14.1 g, 27.9 mmol, 99%) as a colorless solid of mp 181 °C; R = 0.09 (CH2Cl2/MeOH); [α]24D −33.2 (c 0.4, DMSO); 1H NMR (DMSO-d6, 500 MHz) δ 7.47 (bs, 1H), 7.06–7.15 (m, 2H), 5.47 (d, J = 6.1, 1H), 5.10 (d, J = 4.0, 1H), 4.79–4.83 (m, 1H), 4.78 (s, 1H), 4.74 (d, J = 10.1, 1H), 4.61–4.68 (m, 2H), 4.53 (d, J = 4.6, 1H), 4.22 (d, J = 6.7, 1H), 3.70–3.78 (m, 1H), 3.63–3.68 (m, 1H), 3.59–3.63 (m, 1H), 3.48–3.56 (m, 2H), 3.41–3.48 (m, 3H), 3.37–3.41 (d, J = 9.2, 1H), 3.26–3.32 (m, 2H), 3.15–3.23 (m, 1H), 2.23 (s, 3H), 1.26 (s, 9H); 13C{1H} NMR (DMSO-d6, 125 MHz) δ 148.9, 133.9, 133.3, 129.4, 125.3, 122.7, 103.8, 85.9, 80.2, 78.7, 76.4, 75.5, 73.2, 72.2, 70.6, 68.1, 60.4, 60.3, 34.3, 31.1, 19.5; IR νmax 3355, 2958, 2226, 2163, 1362, 1263, 1019, 873, 820, 783, 703 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C23H36O10NaS+, 527.19214; found 527.19208.

4′,6′-Benzylidene-β-d-galactopyranosyl-(1→4)-1-(tert-butyl-2-methylphenyl)thio-β-d-glucopyranoside (15). A solution of 14 (1.00 g, 1.98 mmol) in DMF (10 mL) was treated with benzaldehyde dimethyl acetal (594 μL, 3.96 mmol) and p TsOH (37.7 mg, 198 μmol), and stirred for 1 h at 60 °C. NEt3 (100 μL) was added and the reaction mixture was concentrated in vacuo. The crude product was purified by flash chromatography (CH2Cl2/MeOH 97:3 → 94:6) to give 15 (851 mg, 1.44 mmol, 73%) as a colorless foam of mp 149 °C; R = 0.27 (CH2Cl2/MeOH 95:5); [α]24D −55.3 (c 1.6, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.57 (d, J = 1.5), 7.44–7.50 (m, 2H), 7.28–7.38 (m, 3H), 7.21 (dd, J = 1.5, 7.6, 1H), 7.12 (d, J = 7.9), 5.45 (s, 1H), 4.68 (s, 1H), 4.49–4.56 (m, 2H), 4.45 (d, J = 8.2, 1H), 4.21 (d, J = 12.5, 1H), 4.06 (s, 1H), 3.90–4.01 (m, 2H), 3.77–3.87 (m, 2H), 3.70–3.77 (m, 1H), 3.59–3.67 (m, 2H), 3.55 (d, J = 7.9, 1H), 3.46 (dt, J = 2.1, 9.3, 1H), 3.43 (s, 1H), 3.37 (d, J = 9.2, 1H), 3.22–3.29 (m, 1H), 3.14–3.21 (m, 1H), 2.38 (s, 3H), 1.28 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 149.6, 137.2, 136.7, 131.7, 130.0, 129.6, 129.3, 128.4, 126.4, 125.0, 103.0, 101.4, 88.1, 78.6, 77.7, 76.5, 75.2, 72.31, 72.28, 69.9, 68.9, 67.0, 62.0, 34.4, 31.3, 20.4; IR νmax 3405, 2871, 2345, 1488, 1453, 1363, 1264, 1218, 1165, 1076, 1024, 993, 900, 821, 734, 698 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C30H40O10NaS+, 615.22344; found 615.22352.

4′,6′-Benzylidene-β-d-galactopyranosyl)-(1→4)-6-O-(tert-butyldiphenylsilyl)-1-(tert-butyl-2-methylphenyl)thio-β-d-glucopyranoside (16). A solution of 15 (7.65 g, 12.9 mmol) in pyridine (44 mL) was treated with TBDPSCl (9.10 mL, 35.0 mmol) and stirred for 21 h at room temperature. H2O (100 mL) was added, the aqueous phase was separated and extracted with CH2Cl2 (3 × 100 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in toluene (3 × 40 mL) and concentrated in vacuo again. The crude product was purified by flash chromatography (n-hexane/EtOAc 45:55) to give 16 (6.75 g, 8.13 mmol, 63%) as a colorless foam of mp 113 °C; R = 0.20 (n-hexane/EtOAc 45:55); [α]24D −70.0 (c 1.2, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.80 (dd, J = 6.7, 15.8, 4H), 7.56 (d, J = 1.2, 1H), 7.47–7.53 (m, 2H), 7.31–7.46 (m, 7H), 7.26 (t, J = 7.5, 2H), 7.21 (dd, J = 1.5, 7.9, 1H), 7.15 (d, J = 8.2, 1H), 5.52 (s, 1H), 4.60 (d, J = 9.8, 1H), 4.57 (d, J = 7.6, 1H), 4.42–4.55 (bs, 1H), 4.31 (d, J = 12.5, 1H), 4.12–4.20 (m, 2H), 4.02 (d, J = 11.9, 1H), 3.97 (d, J = 11.3, 1H), 3.93 (t, J = 9.3, 1H), 3.77 (t, J = 8.7, 1H), 3.73 (t, J = 8.7, 1H), 3.54–3.65 (m, 2H), 3.37–3.47 (m, 2H), 2.78–3.03 (m, 3H), 2.45 (s, 3H), 1.15 (s, 9H), 1.08 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 149.4, 137.3, 136.3, 135.9, 135.6, 133.6, 132.6, 132.5, 129.7, 129.64, 129.61, 129.3, 128.9, 128.2, 127.7, 127.6, 126.3, 124.7, 103.1, 101.2, 88.4, 79.0, 78.6, 75.9, 74.9, 72.76, 72.74, 71.3, 68.8, 66.8, 62.5, 34.3, 31.1, 26.8, 20.5, 19.4; IR νmax 3426, 2957, 2858, 2171, 1979, 1733, 1590, 1488, 1460, 1428, 1392, 1362, 1263, 1158, 1084, 1026, 997, 901, 859, 821, 772, 739, 699, 669 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C46H58O10NaSSi+, 853.34122; found 853.33926.

β-d-Galactopyranosyl-(1→4)-6-O-(tert-butyldiphenylsilyl)-1-(tert-butyl-2-methylphenyl)thio-β-d-glucopyranoside (17). A solution of 16 (20.4 g, 24.5 mmol) in CH2Cl2 (120 mL) was treated with FeCl3·6H2O (13.2 g, 49.0 mmol) and stirred for 2 h at room temperature. The reaction mixture was diluted with EtOAc (100 mL) and saturated aqueous NaHCO3 solution (150 mL) was added. The aqueous phase was separated and extracted with EtOAc (3 × 100 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (CH2Cl2/MeOH 93:7) to give 17 (14.0 g, 18.8 mmol, 77%) as a colorless foam of mp 127 °C; R = 0.32 (CH2Cl2/MeOH 9:1); [α]24D −58.7 (c 1.0, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.67–7.78 (m, 4H), 7.42 (s, 1H), 7.28–7.37 (m, 3H), 7.23 (d, J = 6.7, 1H), 7.17 (t, J = 6.5, 2H), 7.02 (d, J = 7.6, 1H), 6.99 (d, J = 7.3, 1H), 5.52 (bs, 1H), 4.90 (bs, 1H), 4.59–4.75 (m, 2H), 4.27–4.59 (m, 3H), 4.00–4.25 (m, 3H), 3.86–4.00 (m, 3H), 3.71–3.86 (m, 3H), 3.57–3.67 (m, 1H), 3.49 (s, 2H), 3.36 (s, 1H), 2.29 (s, 3H), 1.01 (s, 9H), 0.94 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 149.3, 135.8, 135.5, 133.5, 133.0, 132.6, 129.6, 129.5, 127.8, 127.6, 124.4, 102.8, 88.3, 78.9, 76.1, 74.8, 73.9, 72.6, 71.0, 69.5, 62.1, 61.9, 34.1, 31.0, 26.8, 20.4, 19.4; IR νmax 3383, 2930, 2860, 2046, 1428, 1362, 1263, 1148, 1112, 1073, 1026, 895, 822, 784, 740, 701, 669 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C39H54O10NaSSi+, 765.30992; found 765.30832.

2′,3′,4′,6′-Tetra-O-benzoyl-β-d-galactopyranosyl-(1→4)-2,3-di-O-benzoyl-6-O-tert-butyldiphenylsilyl-1-(tert-butyl-2-methylphenyl)thio-β-d-glucopyranoside (18). A solution of 17 (3.97 g, 5.34 mmol) in pyridine (14 mL) was treated with benzoyl chloride (7.44 mL, 64.1 mmol) and stirred for 18 h at room temperature. H2O (50 mL) was added, the aqueous phase was separated and extracted with CH2Cl2 (3 × 50 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in toluene (3 × 20 mL) and concentrated in vacuo again. The crude product was purified by flash chromatography (n-hexane/EtOAc 8:2) to give 18 (7.28 g, 5.32 mmol, 99%) as a colorless foam of mp 107 °C; R = 0.27 (n-hexane/EtOAc 8:2); [α]24D +26.3 (c 1.7, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 8.12 (d, J = 7.3, 2H), 8.01 (dd, J = 7.3, 15.3, 4H), 7.78–7.88 (m, 6H), 7.76 (d, J = 7.3, 2H), 7.68 (d, J = 7.3, 2H), 7.58–7.65 (m, 2H), 7.48–7.57 (m, 6H), 7.28–7.46 (m, 12H), 7.23 (t, J = 7.8, 2H), 7.19 (t, J = 7.8, 2H), 7.12 (q, J = 7.5, 3H), 7.05 (d, J = 7.9, 1H), 5.72–5.79 (m, 2H), 5.67 (dd, J = 8.1, 10.2, 1H), 5.60 (t, J = 9.8, 1H), 5.41 (dd, J = 3.2, 10.5, 1H), 5.21 (d, J = 7.9, 1H), 4.82 (d, J = 10.1, 1H), 4.65 (t, J = 9.8, 1H), 3.98–4.06 (m, 2H), 3.91 (q, J = 11.3, 2H), 3.62 (dd, J = 9.8, 13.4, 1H), 3.38 (d, J = 9.5, 1H), 2.24 (s, 3H), 1.08 (s, 9H), 1.04 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 165.8, 165.6, 165.4, 165.35, 165.3, 164.6, 149.5, 136.8, 136.0, 135.4, 133.6, 133.4, 133.25, 133.2, 133.1, 133.05, 132.9, 131.9, 130.3, 130.2, 130.0, 129.94, 129.89, 129.87, 129.82, 129.77, 129.75, 129.7, 129.55, 129.5, 128.9, 128.8, 128.75, 128.7, 128.5, 128.35, 128.25, 128.2, 128.0, 127.8, 125.1, 100.0, 88.0, 79.0, 74.1, 73.5, 71.8, 71.5, 71.1, 69.9, 68.0, 61.9, 61.3, 34.2, 31.0, 26.9, 20.4, 19.4; IR νmax 2957, 2337, 1984, 1727, 1602, 1490, 1451, 1428, 1314, 1260, 1177, 1088, 1067, 1026, 938, 904, 822, 801, 744 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C81H78O16NaSSi+, 1389.46720; found 1389.46721.

2′,3′,4′,6′-Tetra-O-benzoyl-β-d-galactopyranosyl-(1→4)-2,3-di-O-benzoyl-1-(tert-butyl-2-methylphenyl)thio-β-d-glucopyranoside (10). A solution of 18 (500 mg, 366 μmol) in THF (1.4 mL) was treated with TBAF solution (475 μL, 1M in THF) and stirred for 63 h at room temperature. A saturated aqueous NaHCO3 solution (20 mL) was added, the aqueous phase was separated and extracted with CH2Cl2 (3 × 20 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 8:2 → 75:25) to give 10 (367 mg, 325 μmol, 89%) as a colorless foam of mp 115 °C; R = 0.60 (n-hexane/EtOAc 7:3); [α]24D +38.2 (c 1.4, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.95–8.04 (m, 8H), 7.90 (d, J = 7.3, 2H), 7.74 (d, J = 7.0, 2H), 7.55–7.65 (m, 2H), 7.44–7.55 (m, 7H), 7.32–7.43 (m, 6H), 7.15–7.25 (m, 5H), 7.08 (d, J = 8.2, 1H), 5.74–5.81 (m, 2H), 5.70 (dd, J = 7.9, 10.4, 1H), 5.48–5.55 (m, 2H), 5.02 (d, J = 7.9, 1H), 4.87 (d, J = 10.1, 1H), 4.31 (t, J = 9.6, 1H), 4.08 (t, J = 6.9, 1H), 3.74–3.85 (m, 3H), 3.67 (dd, J = 7.3, 11.3, 1H), 3.46–3.52 (m, 1H), 2.23 (s, 3H), 1.23 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 165.6, 165.40, 165.39, 165.21, 165.19, 164.7, 149.6, 137.1, 133.4, 133.34, 133.29, 133.23, 133.19, 133.1, 131.8, 130.04, 130.02, 129.9, 129.8, 129.70, 129.67, 129.6, 129.4, 129.2, 129.0, 128.9, 128.6, 128.53, 128.51, 128.47, 128.3, 128.19, 128.18, 125.5, 100.9, 87.4, 78.9, 74.7, 74.1, 71.8, 71.1, 70.7, 70.0, 67.6, 60.9, 60.5, 34.3, 31.2, 20.2; IR νmax 3515, 2961, 1981, 1726, 1602, 1585, 1491, 1451, 1315, 1260, 1177, 1089, 1068, 1026, 1001, 936, 853, 825, 801, 686 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C65H60O16NaS+, 1151.34943; found 1151.35059.

2′,3′,4′,6′-Tetra-O-benzoyl-β-d-galactopyranosyl)-(1→4)-2,3-di-O-benzoyl-1-((20-tert-butyldiphenylsilyloxy)eicosyl-1-oxy)-β-d-glucopyranoside (19). A mixture of donor 10 (2.50 g, 2.21 mmol), acceptor 11 (1.47 g, 2.66 mmol) and molecular sieves (5.00 g, 4 Å) in CH2Cl2 (44 mL) was stirred for 2 h at room temperature. It was cooled to −45 °C and TMSOTf (80.0 μL, 442 μmol), BF3·Et2O (56.0 μL, 442 μmol) and NIS (1.49 g, 6.63 mmol) were added. The mixture was stirred for 1.5 h, allowing it to slowly warm to −20 °C, and filtered through Celite®. Saturated aqueous NaHCO3 solution (80 mL) was added, and the water layer was separated and extracted with CH2Cl2 (3 × 100 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 8:2) to give 19 (1.88 g, 1.25 mmol, 57%) as a colorless foam of mp 79 °C; R = 0.59 (n-hexane/EtOAc 7:3); [α]24D +12.2 (c 0.7, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.93–8.03 (m, 8H), 7.88–7.93 (m, 2H), 7.72–7.76 (m, 2H), 7.65–7.70 (m, 4H), 7.50–7.65 (m, 3H), 7.46–7.50 (m, 5H), 7.31–7.45 (m, 12H), 7.22 (t, J = 7.8, 2H), 7.16 (t, J = 7.9, 2H), 5.76–5.79 (m, 1H), 5.72–5.76 (m, 1H), 5.68–5.72 (m, 1H), 5.48 (dd, J = 3.4, 10.4, 1H), 5.39 (dd, J = 7.9, 10.1, 1H), 4.99 (d, J = 7.9, 1H), 4.65 (d, J = 7.9, 1H), 4.25 (t, J = 9.6, 1H), 4.07 (t, J = 7.0, 1H), 3.74–3.86 (m, 4H), 3.62–3.68 (m, 3H), 3.48 (dt, J = 2.1, 9.8, 1H), 3.42 (dt, J = 6.7, 9.8, 1H), 1.92 (dd, J = 4.6, 9.5, 1H), 1.51–1.59 (m, 2H), 1.39–1.51 (m, 2H), 1.30–1.39 (m, 2H), 1.06–1.29 (m, 30H), 1.05 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 165.6, 165.5, 165.4, 165.2, 165.1, 164.7, 135.6, 134.2, 133.5, 133.4, 133.3, 133.2, 133.1, 130.0, 129.8, 129.74, 129.72, 129.68, 129.65, 129.44, 129.43, 129.39, 129.01, 128.9, 128.7, 128.6, 128.54, 128.50, 128.3, 128.23, 128.18, 127.5, 101.3, 100.9, 74.94, 74.93, 72.8, 71.79, 71.76, 71.1, 70.5, 70.1, 67.6, 64.0, 61.0, 60.3, 32.6, 29.71, 29.67, 29.65, 29.6, 29.5, 29.43, 29.37, 29.35, 29.2, 26.8, 25.75, 25.73, 19.2; IR νmax 3071, 2927, 2854, 1727, 1602, 1585, 1492, 1451, 1428, 1315, 1261, 1177, 1092, 1068, 1027, 1000, 936, 854, 824, 802, 742, 704, 686 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C90H104O18NaSi+, 1523.68841; found 1523.68790.

2′,3′,4′,6′-Tetra-O-benzoyl-β-d-galactopyranosyl)-(1→4)-2,3-di-O-benzoyl-1-((20-tert-butyldiphenylsilyloxy)eicosyl-1-oxy)-β-d-glucuronylpyranoside (20). A solution of 19 (137 mg, 91.2 μmol) in CH2Cl2 (608 μL) and H2O (304 μL) was treated with BAIB (73.5 mg, 228 μmol) and TEMPO (5.70 mg, 36.5 μL). The reaction mixture was stirred for 2 h at room temperature. A 10% aqueous Na2S2O3 solution (10 mL) was added, the aqueous phase was separated and extracted with CH2Cl2 (3 × 20 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 1:1 → 3:7) to give 20 (132 mg, 87.1 μmol, 96%) as a colorless foam of mp 80 °C; R = 0.21 (n-hexane/EtOAc/HCO2H 3:7:0.1); [α]24D −1.4 (c 0.6, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 8.60–8.63 (m, 1H), 7.89–8.02 (m, 10H), 7.70–7.74 (m, 2H), 7.65–7.69 (m, 4H), 7.54–7.65 (m, 2H), 7.43–7.52 (m, 6H), 7.31–7.43 (m, 11H), 7.20 (t, J = 7.8, 2H), 7.14 (t, J = 7.8, 2H), 5.74–5.80 (m, 2H), 5.63 (dd, J = 7.9, 10.4, 1H), 5.51–5.57 (m, 1H), 5.45 (dd, J = 7.6, 9.5, 1H), 5.22 (d, J = 7.6, 1H), 4.74 (d, J = 7.6, 1H), 4.49 (t, J = 9.0, 1H), 4.08–4.16 (m, 2H), 3.85 (dt, J = 6.3, 9.8, 1H), 3.67–3.74 (m, 2H), 3.65 (t, J = 6.6, 2H), 3.45 (dt, J = 6.9, 9.8, 1H), 1.51–1.59 (m, 2H), 1.29–1.51 (m, 6H), 1.06–1.29 (m, 28H), 1.04 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 165.7, 165.6, 165.4, 165.3, 165.13, 165.10, 135.6, 134.2, 133.5, 133.3, 133.2, 133.10, 133.07, 133.0, 130.0, 129.74, 129.69, 129.5, 129.44, 129.36, 129.0, 128.7, 128.5, 128.3, 128.21, 128.20, 128.16, 127.5, 124.6, 101.4, 100.5, 76.4, 74.5, 72.4, 71.8, 71.6, 71.1, 70.5, 70.2, 67.9, 64.0, 61.2, 32.6, 29.71, 29.67, 29.66, 29.64, 29.61, 29.5, 29.45, 29.4, 29.3, 26.8, 25.75, 25.7, 19.2; IR νmax 2926, 2854, 1727, 1602, 1585, 1451, 1428, 1315, 1262, 1177, 1091, 1068, 1026, 1000, 936, 854, 823, 802, 742, 704, 686 cm–1; HRMS (ESI) m/z [M + H]+ calcd. for C90H103O9Si+, 1515.68573; found 1515.68235.

2′,3′,4′,6′-Tetra-O-benzoyl-β-d-galactopyranosyl)-(1→4)-2,3-di-O-benzoyl-5-benzoxycarbonyl-1-((20-tert-butyldiphenylsilyloxy)eicosyl-1-oxy)-β-d-glucopyranoside (21). A mixture of 20 (214 mg, 141 μmol), K2CO3 (23.4 mg, 169 μmol) and benzyl bromide (21.7 μL, 183 μmol) in DMF (1.4 mL) was stirred for 2 h at room temperature. Saturated aqueous NH4Cl solution (10 mL) was added, the aqueous phase was separated and extracted with EtOAc (3 × 20 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 85:15) to give 21 (213 mg, 133 μmol, 94%) as a colorless foam of mp 61 °C; R = 0.31 (n-hexane/EtOAc 8:2); [α]24D +2.2 (c 0.8, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 8.07 (d, J = 8.2, 2H), 7.95–8.03 (m, 6H), 7.91 (d, J = 7.9, 2H), 7.74–7.78 (m, 2H), 7.68–7.72 (m, 4H), 7.59–7.65 (m, 2H), 7.46–7.56 (m, 6H), 7.30–7.46 (m, 17H), 7.23 (t, J = 7.9, 2H), 7.14 (t, J = 7.6, 2H), 5.77 (t, J = 9.5, 1H), 5.69 (d, J = 3.4, 1H), 5.55–5.61 (m, 1H), 5.43–5.49 (m, 1H), 5.37 (d, J = 12.2, 1H), 5.31 (dd, J = 3.4, 10.4, 1H), 4.69–4.75 (m, 3H), 4.45 (t, J = 9.3, 1H), 4.13 (dd, J = 0.8, 9.7, 1H), 3.83 (dt, J = 6.3, 9.7, 1H), 3.62–3.76 (m, 5H), 3.47 (dt, J = 6.7, 9.7, 1H), 1.54–1.62 (m, 2H), 1.42–1.54 (m, 2H), 1.33–1.41 (m, 2H), 1.09–1.33 (m, 30H), 1.07 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz) δ 166.9, 165.6, 165.4, 165.24, 165.19, 165.0, 164.9, 135.5, 134.9, 134.1, 133.4, 133.3, 133.2, 133.1, 133.0, 129.9, 129.8, 129.69, 129.66, 129.63, 129.59, 129.41, 129.40, 129.3, 128.9, 128.83, 128.81, 128.76, 128.7, 128.6, 128.5, 128.3, 128.2, 128.1, 127.5, 101.5, 100.3, 76.0, 74.6, 72.3, 71.6, 71.5, 71.0, 70.5, 69.8, 67.6, 67.2, 63.9, 61.1, 32.5, 29.7, 29.64, 29.62, 29.60, 29.57, 29.5, 29.4, 29.3, 29.23, 29.20, 26.8, 25.71, 25.67, 19.2; IR νmax 3070, 2925, 2854, 1728, 1602, 1585, 1492, 1451, 1428, 1315, 1260, 1177, 1090, 1067, 1026, 937, 854, 822, 801, 742, 704, 686 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C97H108O19NaSi+, 1627.71463; found 1627.71130.

2′,3′,4′,6′-Tetra-O-benzoyl-β-d-galactopyranosyl)-(1→4)-2,3-di-O-benzoyl-5-benzoxycarbonyl-1-((20-hydroxyeicosyl-1-oxy)-β-d-glucopyranoside (22). A solution of 21 (209 mg, 130 μmol) in THF (1.1 mL) was treated with TBAF solution (156 μL, 1M in THF) and stirred for 19 h at room temperature. Saturated aqueous NaHCO3 solution (10 mL) was added, the aqueous phase was separated and extracted with CH2Cl2 (3 × 20 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 9:1 → 7:3) to give 22 (139 mg, 102 μmol, 78%) as a colorless foam of mp 66 °C; R = 0.29 (n-hexane/EtOAc 7:3); [α]24D +2.5 (c 0.4, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 8.02–8.05 (m, 2H), 7.92–8.00 (m, 6H), 7.85–7.90 (m, 2H), 7.70–7.75 (m, 2H), 7.58–7.64 (m, 2H), 7.44–7.54 (m, 6H), 7.27–7.44 (m, 11H), 7.22 (t, J = 7.6, 2H), 7.12 (t, J = 7.6, 2H), 5.73 (t, J = 9.5, 1H), 5.65 (d, J = 3.4, 1H), 5.54 (dd, J = 7.6, 10.4, 1H), 5.42 (dd, J = 7.6, 9.8, 1H), 5.33 (d, J = 11.9, 1H), 5.27 (dd, J = 3.4, 10.4, 1H), 4.66–4.71 (m, 3H), 4.41 (t, J = 9.3, 1H), 4.09 (d, J = 9.8, 1H), 3.80 (dt, J = 6.4, 9.8, 1H), 3.69 (t, J = 6.7, 1H), 3.59–3.67 (m, 4H), 3.43 (dt, J = 6.7, 9.8, 1H), 1.52–1.60 (m, 2H), 1.40–1.52 (m, 2H), 0.98–1.39 (m, 32H); 13C{1H} NMR (CDCl3, 125 MHz) δ 166.9, 165.6, 165.4, 165.3, 165.2, 165.1, 164.9, 134.9, 133.4, 133.3, 133.2, 133.1, 133.05, 133.0, 129.8, 129.75, 129.7, 129.65, 129.6, 129.45, 129.4, 129.3, 128.9, 128.85, 128.8, 128.75, 128.7, 128.6, 128.5, 128.3, 128.2, 128.1, 101.5, 100.3, 76.0, 74.6, 72.3, 71.6, 71.5, 71.0, 70.5, 69.8, 67.6, 67.3, 63.0, 61.1, 32.8, 29.7, 29.64, 29.63, 29.61, 29.60, 29.58, 29.56, 29.5, 29.42, 29.41, 29.3, 29.2, 25.7; IR νmax 2926, 2854, 2254, 1728, 1602, 1585, 1493, 1452, 1315, 1263, 1177, 1092, 1068, 1027, 1001, 908, 856, 802, 730, 706 cm–1; HRMS (ESI) m/z [M + H]+ calcd. for C81H91O19+, 1367.61491; found 1367.61305.

2′,3′,4′,6′-Tetra-O-benzoyl-β-d-galactopyranosyl)-(1→4)-2,3-di-O-benzoyl-5-benzoxycarbonyl-1-((20-oxoeicosyl-1-oxy)-β-d-glucopyranoside (8). A solution of 22 (1.00 g, 731 μmol) in CH2Cl2 (14.6 mL) was treated with DMP (467 mg, 1.10 mmol) and the resulting mixture was stirred for 2 h at room temperature. A 10% aqueous Na2S2O3 solution (50 mL) was added, the aqueous phase was separated and extracted with CH2Cl2 (3 × 50 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 82:18) to give 8 (890 mg, 652 μmol, 89%) as a colorless foam of mp 58 °C; R = 0.29 (n-hexane/EtOAc 8:2); [α]24D −5.8 (c 0.3, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 9.76 (t, J = 2.0, 1H), 8.02–8.05 (m, 2H), 7.92–8.00 (m, 6H), 7.85–7.90 (m, 2H), 7.70–7.75 (m, 2H), 7.58–7.64 (m, 2H), 7.46–7.56 (m, 6H), 7.27–7.46 (m, 11H), 7.22 (t, J = 7.6, 2H), 7.12 (t, J = 7.6, 2H), 5.73 (t, J = 9.3, 1H), 5.65 (d, J = 3.7, 1H), 5.54 (dd, J = 7.9, 10.4, 1H), 5.42 (dd, J = 7.6, 9.8, 1H), 5.33 (d, J = 11.9, 1H), 5.27 (dd, J = 3.4, 10.4, 1H), 4.66–4.71 (m, 3H), 4.41 (t, J = 9.3, 1H), 4.09 (d, J = 9.5, 1H), 3.80 (dt, J = 6.4, 9.8, 1H), 3.67–3.72 (m, 1H), 3.59–3.66 (m, 2H), 3.43 (dt, J = 6.7, 9.8, 1H), 2.42 (dt, J = 1.8, 7.3, 2H), 1.62 (q, J = 7.2, 2H), 1.39–1.50 (m, 2H), 0.98–1.35 (m, 32H); 13C{1H} NMR (CDCl3, 125 MHz) δ 203.3, 166.9, 165.6, 165.4, 165.3, 165.2, 165.1, 165.0, 134.9, 133.5, 133.4, 133.2, 133.15, 133.0, 130.0, 129.8, 129.75, 129.70, 129.68, 129.6, 129.46, 129.44, 129.3, 128.89, 128.87, 128.85, 128.80, 128.7, 128.6, 128.5, 128.3, 128.24, 128.15, 100.6, 100.3, 76.0, 74.6, 72.3, 71.6, 71.5, 71.0, 70.6, 69.8, 67.6, 67.3, 61.1, 43.9, 33.4, 29.69, 29.67, 29.66, 29.64, 29.58, 29.54, 29.45, 29.42, 29.35, 29.28, 29.25, 29.23, 29.15, 29.1, 25.7, 24.7; IR νmax 3064, 2924, 2853, 1726, 1602, 1585, 1493, 1451, 1315, 1261, 1177, 1091, 1067, 1026, 1001, 911, 855, 802, 746, 687 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C81H88O19Na+, 1387.58120; found 1387.58412.

2′,3′,4′,6′-Tetra-O-benzoyl-β-d-galactopyranosyl)-(1→4)-2,3-di-O-benzoyl-5-benzoxycarbonyl-1-(22-oxo-24-(S-tert-butylthiocarbonyl)-eicosa-20-enyl-1-oxy)-β-d-glucopyranoside (6). To a solution of phosphonate 9 (34.1 mg, 110 μmol) in THF (1.35 mL) at 0 °C was dropwise added a LiHMDS solution (220 μL, 1M in THF) and the resulting mixture was stirred for 30 min at room temperature, cooled to 0 °C, and treated with a solution of 8 (100 mg, 73.2 μmol) in THF (1.35 mL). After stirring for another 16 h at room temperature, a saturated aqueous NH4Cl solution (20 mL) was added. The aqueous layer was separated and extracted with Et2O (3 × 20 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 85:15) to give 6 (78.0 mg, 51.3 μmol, 70%) as a colorless foam of mp 56 °C and as 1:1.2 mixture of keto/enol tautomers (as to NMR); R = 0.45 (n-hexane/EtOAc 8:2); [α]24D +1.2 (c 0.6, CHCl3); 1H NMR (CDCl3, 500 MHz) of the keto tautomer: δ 8.01–8.06 (m, 2H), 7.91–8.00 (m, 6H), 7.84–7.89 (m, 2H), 7.70–7.75 (m, 2H), 7.58–7.65 (m, 2H), 7.45–7.54 (m, 6H), 7.27–7.43 (m, 11H), 7.22 (t, J = 7.8, 2H), 7.12 (t, J = 7.8, 2H), 6.91 (dt, J = 7.0, 15.9, 1H), 6.15 (dt, J = 1.4, 15.9, 1H), 5.73 (t, J = 9.5, 1H), 5.65 (d, J = 3.7, 1H), 5.53 (dd, J = 7.9, 10.4, 1H), 5.42 (dd, J = 7.5, 9.6, 1H), 5.33 (d, J = 12.2, 1H), 5.27 (dd, J = 3.4, 10.4, 1H), 4.65–4.70 (m, 3H), 4.40 (t, J = 9.5, 1H), 4.09 (d, J = 9.8, 1H), 3.80 (dt, J = 6.3, 9.8, 1H), 3.70 (bs, 2H), 3.68 (d, J = 6.7, 1H), 3.61–3.65 (m, 2H), 3.43 (dt, J = 6.7, 9.8, 1H), 2.23 (q, J = 6.7, 1H), 2.17 (q, J = 6.7, 1H), 1.51 (s, 4.5H), 1.47 (s, 5.5H), 1.40–1.45 (m, 2H), 1.05–1.35 (m, 32H); 1H NMR (CDCl3, 500 MHz) of the enol tautomer: δ 12.62 (d, J = 1.5, 1H), 8.01–8.06 (m, 2H), 7.91–8.00 (m, 6H), 7.84–7.89 (m, 2H), 7.70–7.75 (m, 2H), 7.58–7.65 (m, 2H), 7.45–7.54 (m, 6H), 7.27–7.43 (m, 11H), 7.22 (t, J = 7.8, 2H), 7.12 (t, J = 7.8, 2H), 6.70 (dt, J = 7.0, 15.6, 1H), 5.73 (t, J = 9.5, 1H), 5.68 (s, 1H), 5.65 (d, J = 3.7, 1H), 5.53 (dd, J = 7.9, 10.4, 1H), 5.42 (dd, J = 7.5, 9.6, 1H), 5.33 (d, J = 12.2, 1H), 5.31 (s, 1H), 5.27 (dd, J = 3.4, 10.4, 1H), 4.65–4.70 (m, 3H), 4.40 (t, J = 9.5, 1H), 4.09 (d, J = 9.8, 1H), 3.80 (dt, J = 6.3, 9.8, 1H), 3.68 (d, J = 6.7, 1H), 3.61–3.65 (m, 2H), 3.43 (dt, J = 6.7, 9.8, 1H), 2.23 (q, J = 6.7, 1H), 2.17 (q, J = 6.7, 1H), 1.51 (s, 4.5H), 1.47 (s, 5.5H), 1.40–1.45 (m, 2H), 1.05–1.35 (m, 32H); 13C{1H} NMR (CDCl3, 125 MHz) δ 196.4, 192.7, 191.8, 166.9, 166.7, 165.6, 165.4, 165.3, 165.2, 165.1, 165.0, 150.8, 142.8, 134.9, 133.5, 133.4, 133.2, 133.11, 133.07, 130.1, 130.0, 129.8, 129.72, 129.69, 129.66, 129.6, 129.5, 129.44, 129.42, 129.3, 128.87, 128.86, 128.83, 128.77, 128.7, 128.6, 128.5, 128.31, 128.29, 128.2, 128.1, 124.0, 101.5, 100.3, 100.2, 76.0, 74.6, 72.3, 71.6, 71.5, 71.0, 70.6, 69.8, 67.6, 67.3, 61.1, 56.1, 48.9, 48.2, 32.7, 32.6, 30.1, 29.69, 29.67, 29.65, 29.62, 29.59, 29.53, 29.51, 29.49, 29.43, 29.40, 29.36, 29.26, 29.23, 29.15, 29.1, 28.4, 27.9, 25.7; IR νmax 3446, 2925, 2854, 2357, 1729, 1655, 1602, 1585, 1452, 1365, 1316, 1261, 1177, 1091, 1069, 1026, 907, 858, 801, 729, 706 cm–1; HRMS (ESI) m/z [M + Na]+ calcd. for C89H100O20NaS+, 1543.64209; found 1543.63997.

4-Benzyl 1-methyl N-(E)-24-[((2′′,3′′,4′′,6′′-tetra-O-benzoyl-β-d-galactopyranosyl)-(1→4)-2′,3′-di-O-benzoyl-5′-benzoxycarbonyl-β-d-glucopyranosid-1′-yloxy))-tetraeicos-4-enoyl]-N-methyl-d-aspartate (23). A mixture of 6 (500 mg, 329 μmol), 7 (99.0 mg, 394 μmol) and NEt3 (91.6 μL, 657 μmol) in THF (16 mL) was treated with AgO2CCF3 (87.0 mg, 394 μmol) at 0 °C and stirred for 3 h at 0 °C. Saturated aqueous NH4Cl solution (30 mL) was added, the aqueous phase was separated and extracted with Et2O (3 × 30 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography (n-hexane/EtOAc 7:3) to give 23 (468 mg, 278 μmol, 85%) as a colorless foam of mp 63 °C and as a 1:3 mixture of keto/enol tautomers; R = 0.26 (n-hexane/EtOAc 7:3); [α]24D +14.4 (c 0.7, CHCl3); 1H NMR (CDCl3, 500 MHz) of the keto tautomer: δ 8.02–8.06 (m, 2H), 7.92–8.00 (m, 6H), 7.85–7.90 (m, 2H), 7.71–7.75 (m, 2H), 7.58–7.64 (m, 2H), 7.44–7.54 (m, 6H), 7.27–7.43 (m, 16H), 7.22 (t, J = 7.8, 2H), 7.12 (t, J = 7.9, 2H), 6.91–6.99 (m, 1H), 6.12–6.18 (m, 1H), 5.73 (t, J = 9.5, 1H), 5.65 (d, J = 3.4, 1H), 5.54 (dd, J = 7.8, 10.2, 1H), 5.42 (dd, J = 7.5, 9.6, 1H), 5.33 (d, J = 12.2, 1H), 5.27 (dd, J = 3.4, 10.4, 1H), 5.12–5.15 (m, 2H), 4.90 (dd, J = 6.3, 7.8, 1H), 4.66–4.71 (m, 3H), 4.41 (t, J = 9.3, 1H), 4.09 (d, J = 9.8, 1H), 3.80 (dt, J = 6.4, 9.8, 1H), 3.68–3.71 (m, 4H), 3.60–3.65 (m, 4H), 3.43 (dt, J = 6.7, 9.8, 1H), 3.20 (dt, J = 5.6, 16.5, 1H), 3.02 (s, 3H), 2.89 (ddd, J = 1.5, 8.5, 16.5, 1H), 2.14–2.25 (m, 2H), 1.58–1.63 (m, 2H), 1.40–1.49 (m, 4H), 1.05–1.35 (m, 30H); 1H NMR (CDCl3, 500 MHz) of the enol tautomer: δ 14.00 (d, J = 0.9, 1H), 8.02–8.06 (m, 2H), 7.92–8.00 (m, 6H), 7.85–7.90 (m, 2H), 7.71–7.75 (m, 2H), 7.58–7.64 (m, 2H), 7.44–7.54 (m, 6H), 7.27–7.43 (m, 16H), 7.22 (t, J = 7.8, 2H), 7.12 (t, J = 7.9, 2H), 6.65 (dt, J = 7.4, 15.3, 1H), 5.79 (dd, J = 1.1, 15.4, 1H), 5.73 (t, J = 9.5, 1H), 5.65 (d, J = 3.4, 1H), 5.54 (dd, J = 7.8, 10.2, 1H), 5.42 (dd, J = 7.5, 9.6, 1H), 5.33 (d, J = 12.2, 1H), 5.27 (dd, J = 3.4, 10.4, 1H), 5.12–5.15 (m, 2H), 5.07 (s, 1H), 4.98–5.04 (m, 1H), 4.66–4.71 (m, 3H), 4.41 (t, J = 9.3, 1H), 4.09 (d, J = 9.8, 1H), 3.80 (dt, J = 6.4, 9.8, 1H), 3.68–3.71 (m, 4H), 3.60–3.65 (m, 2H), 3.43 (dt, J = 6.7, 9.8, 1H), 3.20 (dt, J = 5.6, 16.5, 1H), 2.99 (s, 3H), 2.89 (ddd, J = 1.5, 8.5, 16.5, 1H), 2.14–2.25 (m, 2H), 1.58–1.63 (m, 2H), 1.40–1.49 (m, 4H), 1.05–1.35 (m, 30H); 13C{1H} NMR (CDCl3, 125 MHz) δ 192.9, 172.5, 170.7, 170.5, 170.1, 168.7, 167.5, 166.9, 165.6, 165.4, 165.3, 165.2, 165.1, 164.9, 150.5, 140.6, 134.9, 133.5, 133.4, 133.19, 133.18, 133.11, 133.06, 130.0, 129.8, 129.73, 129.70, 129.67, 129.6, 129.5, 129.4, 129.3, 129.2, 128.89, 128.86, 128.84, 128.77, 128.7, 128.62, 128.55, 128.5, 128.3, 128.2, 128.1, 125.1, 101.5, 100.3, 87.7, 76.0, 74.6, 72.3, 71.6, 71.5, 71.0, 70.6, 69.8, 67.6, 67.3, 66.7, 61.1, 56.9, 56.1, 52.6, 52.5, 47.4, 36.0, 34.8, 34.6, 34.2, 32.61, 32.57, 29.71, 29.68, 29.66, 29.64, 29.57, 29.54, 29.46, 29.45, 29.38, 29.27, 29.24, 29.22, 29.21, 28.6, 28.0, 25.7, 23.8; IR νmax 2925, 2854, 1730, 1656, 1601, 1492, 1452, 1374, 1315, 1264, 1177, 1093, 1069, 1027, 910, 852, 803, 708 cm–1; HRMS (ESI) m/z [M + H]+ calcd. for C98H108O24N+, 1682.72558; found 1682.72416.

4-Benzyl 1-methyl N-(E)-24-[((2′′,3′′,4′′,6′′-tetra-O-benzoyl-β-d-galactopyranosyl)-(1→4)-2′,3′-di-O-benzoyl-5′-carboxyl-β-d-glucopyranosid-1′-yloxy))-tetraeicosanoyl]-N-methyl-d-aspartate (5). A solution of 23 (240 mg, 143 μmol) in EtOAc (7 mL) was treated with 10% Pd/C (120 mg, 50 wt%). The resulting mixture was stirred under a hydrogen atmosphere for 19 h at room temperature and then filtered through Celite® to give 5 (200 mg, 133 μmol, 93%) as a colorless foam of mp 105 °C and as a 1:4 mixture of keto and enol tautomers; R = 0.19 (CH2Cl2/MeOH/HCO2H 95:5:0.1); [α]24D +12.3 (c 0.6, CHCl3); 1H NMR (CDCl3, 500 MHz) of the keto tautomer: δ 7.93–8.02 (m, 8H), 7.91 (d, J = 7.6, 2H), 7.71 (d, J = 7.6, 2H), 7.53–7.65 (m, 2H), 7.43–7.51 (m, 5H), 7.28–7.43 (m, 7H), 7.18 (t, J = 7.8, 2H), 7.13 (t, J = 7.8, 2H), 5.73–5.81 (m, 2H), 5.57–5.69 (m, 2H), 5.41–5.49 (m, 1H), 5.19 (d, J = 7.3, 1H), 4.88–5.02 (m, 1H), 4.74 (d, J = 7.3, 1H), 4.47 (t, J = 9.2, 1H), 4.20 (t, J = 6.3, 1H), 4.11 (d, J = 9.5, 1H), 3.84 (dt, J = 6.4, 9.5, 1H), 3.78–3.83 (m, 2H), 3.71–3.78 (m, 3H), 3.63–3.71 (m, 2H), 3.45 (dt, J = 6.7, 9.5, 1H), 3.23 (dd, J = 6.1, 7.1, 1H), 2.91 (dd, J = 7.9, 17.1, 1H), 2.80–2.87 (s, 3H), 2.48–2.58 (m, 2H), 1.51–1.61 (m, 2H), 1.39–1.51 (m, 2H), 1.05–1.35 (m, 34H); 1H NMR (CDCl3, 500 MHz) of the enol tautomer: δ 7.93–8.02 (m, 8H), 7.91 (d, J = 7.6, 2H), 7.71 (d, J = 7.6, 2H), 7.53–7.65 (m, 2H), 7.43–7.51 (m, 5H), 7.28–7.43 (m, 7H), 7.18 (t, J = 7.8, 2H), 7.13 (t, J = 7.8, 2H), 5.73–5.81 (m, 2H), 5.57–5.69 (m, 2H), 5.41–5.49 (m, 1H), 5.19 (d, J = 7.3, 1H), 4.88–5.02 (m, 1H), 4.74 (d, J = 7.3, 1H), 4.47 (t, J = 9.2, 1H), 4.20 (t, J = 6.3, 1H), 4.11 (d, J = 9.5, 1H), 3.84 (dt, J = 6.4, 9.5, 1H), 3.71–3.78 (m, 3H), 3.63–3.71 (m, 2H), 3.60 (s, 1H), 3.45 (dt, J = 6.7, 9.5, 1H), 3.23 (dd, J = 6.1, 7.1, 1H), 3.00–3.08 (m, 3H), 2.91 (dd, J = 7.9, 17.1, 1H), 2.48–2.58 (m, 2H), 1.51–1.61 (m, 2H), 1.39–1.51 (m, 2H), 1.05–1.35 (m, 34H); 13C{1H} NMR (CDCl3, 125 MHz) δ 204.9, 204.2, 179.6, 174.9, 172.3, 170.9, 170.6, 169.8, 169.6, 168.1, 165.7, 165.6, 165.4, 165.3, 165.2, 165.1, 133.4, 133.23, 133.20, 133.12, 133.10, 129.9, 129.7, 129.64, 129.62, 129.5, 129.4, 129.23, 129.20, 128.9, 128.6, 128.5, 128.26, 128.25, 128.2, 128.1, 101.4, 100.3, 76.1, 74.0, 72.3, 71.7, 71.4, 71.0, 70.5, 70.3, 67.9, 61.2, 60.5, 57.3, 56.7, 53.0, 52.7, 49.1, 48.9, 43.2, 43.0, 35.9, 33.8, 29.61, 29.58, 29.54, 29.48, 29.43, 29.38, 29.35, 29.32, 29.28, 29.2, 28.97, 28.95, 25.6, 23.4, 21.0, 14.1; IR νmax 2925, 2853, 1726, 1602, 1585, 1492, 1451, 1315, 1263, 1177, 1092, 1068, 1026, 1000, 936, 854, 803, 706, 686 cm–1; HRMS (ESI) m/z [M + H]+ calcd. for C84H98O24N+, 1504.64733; found 1504.64872.

Ancorinoside B (2). A solution of 5 (129 mg, 85.7 μmol) in MeOH (8.6 mL) was treated with NaOMe solution (117 μL, 25 wt% in MeOH) and stirred for 30 min at 50 °C. The reaction mixture was cooled to room temperature, acidified with DOWEX 50WX8-100® resin and filtered. The solution was washed with heptane (25 mL) and concentrated in vacuo. The residue was recrystallized from MeOH to give 2 (56.0 mg, 66.0 μmol, 77%) as a beige solid of mp 101 °C; [α]24D +3.2 (c 0.1, MeOH); 1H NMR (CDCl3, 500 MHz) δ 4.37 (d, J = 7.3, 1H), 4.35 (d, J = 7.6, 1H), 4.04–4.08 (m, 1H), 3.97 (d, J = 9.8, 1H), 3.85 (dt, J = 6.7, 9.5, 1H), 3.75–3.81 (m, 3H), 3.69 (dd, J = 4.6, 11.3, 1H), 3.54–3.59 (m, 3H), 3.52 (d, J = 7.3, 1H), 3.47 (dd, J = 3.1, 9.8, 1H), 3.26–3.29 (m, 1H), 2.96 (s, 3H), 2.91 (dd, J = 4.7, 17.0), 2.78–2.87 (m, 3H), 1.64–1.70 (m, 2H), 1.57–1.64 (m, 2H), 1.24–1.44 (m, 34H); 13C{1H} NMR (CDCl3, 125 MHz) δ 178.2, 173.2, 172.1, 104.9, 104.7, 81.4, 77.3, 76.2, 75.2, 74.8, 74.5, 72.6, 71.4, 70.4, 68.3, 62.6, 34.6, 33.4, 30.91, 30.89, 30.85, 30.8, 30.72, 30.68, 30.5, 30.4, 27.4, 27.21, 27.19, 27.0; IR νmax 3349, 2920, 2851, 2204, 2033, 1725, 1628, 1495, 1470, 1425, 1249, 1162, 1072, 1033, 951, 914, 770, 718, 635 cm–1; HRMS (ESI) m/z [M − H]− calcd. for C41H68O17N–, 846.44818; found 846.44967.

Ancorinoside B tris(diethylammonium) salt. A solution of 2 (15.0 mg, 17.7 μmol) in MeOH (885 μL) was treated with HNEt2 (11 μL, 106 μmol) and stirred for 1 h at room temperature. The reaction mixture was concentrated in vacuo to give the ammonium salt (18.7 mg, 17.5 μmol, 99%) as a brown solid of mp 57 °C; [α]24D +5.0 (c 0.1, MeOH); 1H NMR (CDCl3, 500 MHz) δ 4.35 (d, J = 7.3, 1H), 4.30 (d, J = 7.9, 1H), 3.90–3.95 (m, 1H), 3.82–3.89 (m, 1H), 3.77–3.79 (m, 1H), 3.73–3.77 (m, 1H), 3.69–3.73 (m, 1H), 3.66–3.69 (m, 1H), 3.59–3.62 (m, 1H), 3.56–3.59 (m, 1H), 3.54–3.56 (m, 1H), 3.52–3.54 (m, 1H), 3.49–3.52 (m, 1H), 3.48 (dd, J = 3.5, 9.9, 1H), 3.27–3.29 (m, 1H), 3.02 (q, J = 7.0, 12H), 2.91 (s, 3H), 2.80–2.84 (m, 1H), 2.76–2.80 (m, 1H), 2.70–2.76 (m, 1H), 2.13 (dd, J = 9.2, 15.3), 1.58–1.66 (m, 2H), 1.51–1.58 (m, 2H), 1.24–1.43 (m, 54H); 13C{1H} NMR (CDCl3, 125 MHz) δ 197.8, 196.7, 179.9, 176.5, 176.1, 105.6, 104.3, 102.4, 83.6, 77.4, 77.3, 76.8, 75.1, 74.7, 72.8, 71.2, 70.4, 64.7, 62.6, 43.6, 41.7, 41.1, 31.2, 31.0, 30.95, 30.90, 30.8, 30.7, 30.6, 27.8, 27.6, 27.3, 27.2, 11.9; IR νmax 3375, 2920, 2851, 2510, 2323, 2049, 1591, 1456, 1394, 1258, 1160, 1053, 784, 672 cm–1; HRMS (ESI) m/z [M − H]− calcd. for C53H103O17N4–, 1067.73127; found 1067.73446.

3.3. Antimicrobial Assay

Minimum Inhibitory Concentrations (MIC) of ancorinoside B (2) were ascertained by serial dilution assays as reported previously [15,16] employing the following microorganisms as provided by the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH, (Braunschweig, Germany) or the ATCC-American Type Culture Collection (Manassas, VA, USA): Pichia anomala, Schizosaccharomyces pombe, Mucor hiemalis, Candida albicans, and Rhodotorula glutinis for fungal microorganisms; Bacillus subtilis, Staphyloccocus aureus and Mycobacterium smegmatis for Gram-positive bacteria, Acinetobacter baumannii, Chromobacterium violaceum, Escherichia coli and Pseudomonas aeruginosa for Gram-negative bacteria. For accession numbers cf Table 1.

3.4. Inhibition of Biofilm Formation

Staphylococcus aureus DSM 1104 samples were taken from a –20 °C stock and incubated overnight in 25 mL CASO (casein-peptone soymeal-peptone) medium at 37 °C while shaking (100 rpm). The OD600 of the culture solution was adjusted to match the turbidity of a 0.001 McFarland standard. 150 µL of CASO with 4% glucose broth was added as well as serially diluted compounds (250–0.13 µg/mL) and incubated in 96 well microtiter plates (TPP tissue culture ref. no. 92196) at 37 °C for 18 h. Any resulting biofilm inhibition was evaluated via staining with 0.1% crystal violet (Thermo Fisher, Waltham, MA, USA) following established protocols [12,17] In brief, the supernatant was discarded, the biofilm stained at room temperature with 0.1% crystal violet for 15 min and washed thrice with PBS (phosphate-buffered saline) buffer. The dye in the biofilm was extracted with 30% acetic acid, and the absorbance was quantified with a plate reader (Synergy 2, BioTek, Santa Clara, CA, USA) at 550 nm. DMSO (2.5%) served as a negative control and microporenic acid A [12] (250–0.13 µg/mL) as a positive control. All experiments were run in duplicates with two repetitions. SD of two repeats with duplicates each were 10% or less.

P. aeruginosa (PA 14) DSM 19882 was grown in 25 mL LB medium (Luria-Bertani Broth) in a 250 mL flask at 37 °C, shaking at 100 rpm for 18 h. The OD600 of the culture solution was adjusted to 0.1 McFarland standard in M63 medium, supplemented with magnesium sulfate, glucose, and casamino acids as previously described [18]. The compounds were added to 150 μL bacterial solution at various concentrations (250–2 μg/mL), then the solution was added to U-bottom 96-well plates (Falcon non-tissue plate with U-bottom ref. no. 351177). The plates were incubated at 37 °C at 150 rpm for 24 h and biofilms were established at the air-liquid interface. The plates were rinsed once with PBS buffer, the biofilms were stained by 150 μL 0.1% CV at room temperature for 15 min and then rinsed twice with PBS buffer. The absorbance was quantified with a plate reader (Synergy 2, BioTek, Santa Clara, CA, USA) at 550 nm using ethanol (95%). DMSO (2.5%) and myxovalargin A (250–2 μg/mL) were used as negative and positive controls.

3.5. Biofilm Dispersion Assay

A cell suspension of Staphylococcus aureus strain DSM 1104 was adjusted to match the turbidity of a 0.001 McFarland standard and incubated in 96 well tissue microtiter plates for 18 h in CASO plus 4% glucose broth. The supernatant was removed from the wells which were washed with 150 µL PBS buffer. 150 µL of fresh medium (CASO with 4% glucose broth) was added together with serially diluted compounds (250–0.13 µg/mL). The plates were incubated for a further 24 h at 37 °C. Staining of the preformed biofilm and controls was done as described for the biofilm inhibition [12,17]. All experiments were run in duplicates with two repetitions (SD ≤ 10%).

Candida albicans DSM 11225 was cultured in 25 mL YPED (Yeast extract Peptone Dextrose) medium in a 250 mL flask at 30 °C in a shaker (100 rpm) for 18 h. The OD600 of the suspension was adjusted to 0.05 McFarland standard in RPMI 1640 medium. 150 μL solution was added to 96 well non-tissue microtiter plates (Falcon non-tissue plate ref. no. 351172) at 37 °C at 150 rpm. After 90 min the supernatant was removed and the plates were washed twice with PBS buffer. The test compounds were serially diluted in 150 μL of fresh medium (RPMI 1640) to various concentrations (250–2 μg/mL) and added to the wells. DMSO (2.5%) and farnesol (250–2 μg/mL) served as negative and positive controls. The plates were incubated at 37 °C at 150 rpm for 24 h, the supernatant was discarded, and the biofilms were stained by 150 μL 0.1% CV at room temperature for 25 min after having been washed once with PBS buffer. The plates were washed four times with PBS buffer. The biofilms were dissolved in 150 μL ethanol (95%) and the absorbance was quantified with a plate reader (Synergy 2, BioTek, Santa Clara, CA, USA) at 610 nm. All experiments were run in duplicates with two repetitions (SD ≤ 10%).

3.6. Cytotoxicity Assay

Cytotoxic effects on human endocervical adenocarcinoma KB-3-1 (ACC 158) cells and mouse fibroblasts L929 (ACC 2) upon treatment with ancorinoside B (2) or epothilone B as a positive control were determined by standard MTT assays [19].

3.7. Human Cancer Cell MMP Assay (Gelatin Zymography)

Cell lines, culture conditions, and stock solutions. 518A2 human melanoma cells (Department of Radiotherapy and Radiobiology, University Hospital Vienna, Vienna, Austria) were grown in Dulbecco’s Modified Eagle Medium (DMEM; Pan Biotec, Aidenbach, Germany) supplemented with 10% (v/v) fetal bovine serum (FBS; Biochrom, Berlin, Germany) and 1% (v/v) Antibiotic-Antimycotic solution (Gibco, Waltham, MA, USA). Cells were incubated at 37 °C, 5% CO2, 95% humidified atmosphere, and were serially passaged following trypsinization by using 0.05% trypsin/0.02% EDTA (w/v; Biochrom, GmbH, Berlin, Germany). Mycoplasma contamination was frequently monitored, and only mycoplasma-free cultures were used. 10 mM stock solutions of test compounds were prepared in DMSO and stored at −23 °C.

Assessment of MMP-2 and MMP-9 activity by gelatin zymography [20]. The influence of test compounds on expression respectively secretion of matrix metalloproteases (MMP) of type-2 and -9 in 518A2 melanoma cells was assessed by gelatin zymography. Cells were seeded with 3 mL per well in 6 well plates with a cell density of 0.1 × 106 cells per mL, followed by an incubation period of 24 h at standard cell culture conditions. The medium was aspirated and replaced by 1.5 mL DMEM and 5 µL per well aprotinin solution of a 10 mg/mL stock solution was added. 15 µL per well of 100-fold concentrated test compound dilutions were added, resulting in final concentrations of 500 nM, 1 µM, 25 µM, and 50 µM, as well as the corresponding amount of DMSO as a negative control. Treated cells were incubated for a further 24 h under standard cell culture conditions. Harvesting started with transferring the supernatant of each well into a fresh 2 mL micro reaction tube, followed by rinsing each well with 500 µL of phosphate-buffered saline (PBS). Then 500 µL of cell lysis buffer (0.1 M Tris-Cl, 0.2% Triton X 100 ad ddH2O, pH 7.4, immediately before use: addition of 10 µL aprotinin solution (10 mg/mL stock per 3 mL buffer) were added, and cells were detached using a cell scraper. Cell lysates were also transferred to fresh 2 mL micro reaction tubes, vortexed for at least 10 s, and incubated on ice for a further 15 min. Supernatant and cell lysate samples were centrifuged (20 min, 30,000× g, 4 °C). The supernatant of each tube was transferred into a fresh tube. The protein concentration of each sample was determined using a standard Bradford assay. Samples were prepared to contain 80 µg protein, non-reducing 5× protein sample buffer (10% sodium dodecyl sulfate (SDS), 0.5 M Tris-Cl, 1:1 glycerol, bromophenol blue) was added, and samples were loaded on a polyacrylamide gel, composed of 4% collecting gel and 10% separating gel containing 1 mg/mL gelatin. Electrophoresis was conducted for 30 min with 80 V and for 2–3 h with 100 V. The gels were washed 10 min each in washing buffer I (50 mM Tris-Cl, 2% Triton X 100, ad ddH2O, pH 7.4) and washing buffer II (50 mM Tris-Cl, ad ddH2O, pH 7.4), followed for incubation in substrate buffer (50 mM Tris-Cl, 1% Triton X 100, 5 mM CaCl2, ad ddH2O, pH 7.4) for 16 h at 37 °C. The gels were stained for 30 min in Coomassie gel staining solution (500 mg Coomassie brilliant blue, 454 mL MeOH, 454 mL ddH2O, 100 mL acetic acid glacial) and destained for 1–2 h in destaining solution (500 mL MeOH, 100 mL acetic acid glacial, 1.4 L ddH2O) until light bands became visible. Gels were documented and densitometrically evaluated using AzureSpot analysis software. All experiments were run in duplicates with two repetitions.

4. Conclusions

The first synthesis of the marine sponge metabolite ancorinoside B (2) proceeded with an overall yield of 4% over 16 steps in the longest linear reaction sequence. Its modular character should also allow for the synthesis of other, including non-natural, oligoglycosidic 3-acyltetramic acids with variance in the sugars, the tether length, and functionalization, as well as in the amino acid constituting the tetramate moiety. This is of medicinal interest, as Fusetani et al. had already observed that slight structural changes in 3-acyltetramic acids can lead to significantly different inhibitory effects on the activity of cellular matrix metalloproteinases which are essential enzymes in the tumoral metastasis cascade. The remarkably strong antibiofilm effects of ancorinoside B (2) at concentrations not toxic to the constituent microorganisms, and its reducing effect on the secretion and expression of matrix metalloproteinases 2 and 9 make it a promising candidate for application as a pleiotropic agent in a medicinal context, e.g., for the control of the general hospital, catheter, or joint protheses infections.